| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.093 | 0 |
| Total Income - EUR | 12.120 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.409 | 0 |
| Total Expenses - EUR | 15.629 | 896 | 581 | 552 | 63 | 62 | 61 | 175 | 9.273 | 2.319 |
| Gross Profit/Loss - EUR | -3.509 | -896 | -581 | -552 | -63 | -62 | -61 | -175 | -5.864 | -2.319 |
| Net Profit/Loss - EUR | -3.872 | -896 | -581 | -552 | -63 | -62 | -61 | -175 | -5.864 | -2.319 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Veritamed Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.710 | 1.030 | 497 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 3.484 | 843 | 796 | 717 | 640 | 565 | 492 | 289 | 11.455 | 2.705 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.014 | 3 |
| Cash | 3.484 | 843 | 796 | 717 | 640 | 565 | 492 | 289 | 10.440 | 2.701 |
| Shareholders Funds | 4.316 | 1.037 | 439 | -122 | -183 | -241 | -297 | -472 | -6.335 | -8.618 |
| Social Capital | 90 | 89 | 88 | 86 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | 878 | 835 | 854 | 839 | 822 | 807 | 789 | 761 | 17.789 | 11.323 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8621 - 8621" | |||||||||
| CAEN Financial Year |
8621
|
|||||||||
Comments - Veritamed Srl